PR Newswire All News ReleasesCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 07:53:00·⟳ 抓取 07:54:30 +1m30s·⚡ 决策 09-01 07:55:56 +1m26s·56.8 天前
Rosen 律所再次征集 Disc Medicine 投资者参与潜在证券集体诉讼调查
当前 PR Newswire 公告不是新的 FDA 监管进展，也不是已正式立案或披露金额的证券诉讼，而是基于旧 CRL 的重复律所广告式征集；新增信息不足以支持做空或做多。
📄 原文PR Newswire All News Releases↗ 原文
NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigat…
不做 Disc Medicine, Inc.（IRON.US）
不做：本条为基于 2026-02-13 CRL 的重复律所索赔征集，未新增诉讼立案、监管进展、赔偿量级或基本面损害；做空催化不够强且已充分传播。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Disc Medicine 的实质负面催化是 2026-02-13 FDA 对 bitopertin 发出 CRL，该事实已由公司和 SEC 8-K 披露并在当日股价中反映。本次 2026-08-31 Rosen 律所稿件仅重复征集投资者，且相同 case_id 与内容在过去数月多次发布，没有新增监管结论、诉讼进展、赔偿量级或基本面变化，因此不形成新的可交易 edge。
消息传播链
- Disc Medicine 首次公告 FDA 对 bitopertin EPP NDA 发出 CRL，并称 FDA 需要看到正在进行的 Phase 3 APOLLO 结果。市场反应:Rosen 稿件称 IRON 当日下跌 22%。
- Disc Medicine 向 SEC 提交 8-K，确认收到 CRL 并附公告及 CRL。
- Rosen Law Firm 已在 2026-08-17 发布几乎相同的 IRON 投资者索赔征集稿，说明本次 2026-08-31 不是首次传播。
- 本次信号为 Rosen Law Firm 再次发布的投资者征集公告，未新增 CRL 之外的实质事实。
主要风险
- 若后续出现正式集体诉讼立案、法院受理、监管调查或公司新增 FDA 沟通失败，才可能构成新的负面催化。
- bitopertin CRL 本身仍是 Disc Medicine 的基本面风险，但本条公告未改变该风险的状态或量级。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-17 · 影响 invalidates
同一律所、同一 case_id 的索赔征集已在本次前多次发布，削弱将 2026-08-31 稿件视为新做空催化的理由。
检索:Disc Medicine bitopertin CRL Rosen Law Firm investigation repeated August 2026 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-06-09 · 影响 weakens
Disc Medicine 6 月称已与 FDA 对齐，若 APOLLO 成功可作为 CRL 回复基础，说明 CRL 后续路径已有公开更新，本条 Rosen 稿未新增监管恶化。
检索:Disc Medicine FDA Type A meeting bitopertin CRL response June 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足未影响结论；关键判断来自官方 CRL 首发时间和多次重复传播。
方向:未使用历史先例定方向；本条已由重复旧闻属性决定不交易。
涨幅量级:无新增可交易催化，不需要用同类事件校准涨跌幅。
形态:律所重复征集类公告通常更接近传播噪音，但本轮未以先例作为核心依据。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,851 字
NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
So What: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=56641 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
What is this about: On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA that would need additional evidence.
On this news, Disc Medicine's stock price fell 22% on February 13, 2026.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. The Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
So What: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=56641 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
What is this about: On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA that would need additional evidence.
On this news, Disc Medicine's stock price fell 22% on February 13, 2026.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. The Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。